TABLE 3

Possible ADRs due to antibiotic use between treatment arms

Group or ADRNo. (%) of patients in the following polymyxin treatment arm:P value
MT (n = 58)NVCT (n = 203)VCT (n = 30)
All patients with an ADR18 (31.0)89 (43.8)12 (40.0)0.215
Patients in which the ADR resolveda14 (77.8)63 (70.8)10 (83.3)0.545
Nephrotoxicity based on RIFLE criteria16 (27.6)74 (36.5)8 (26.7)0.313
    Risk of renal dysfunction8 (13.8)20 (9.9)4 (13.3)0.637
    Injury to the kidney5 (8.6)31 (15.3)0 (0.0)0.038
    Failure of kidney function3 (5.2)22 (10.8)3 (10.0)0.434
    Loss of kidney function0 (0.0)0 (0.0)1 (3.3)0.013
    End-stage kidney disease0 (0.0)1 (0.5)0 (0.0)0.805
Nephrotoxicity not included in the RIFLE criteriab0 (0.0)4 (2.0)1 (3.3)0.460
Total incidence of nephrotoxicityc16 (27.6)78 (38.4)9 (30.0)0.254
Neurotoxicity1 (1.7)10 (4.9)1 (3.3)0.543
Hepatotoxicity2 (3.4)8 (3.9)0 (0.0)0.542
Othersd2 (3.4)13 (6.4)3 (10.0)0.468
  • a The percentages in parentheses refer to the percentage of patients who experienced a resolution of the adverse drug reactions among all patients who experienced adverse drug reactions.

  • b These patients experienced electrolyte imbalances due to nephropathy without a concomitant rise in the serum creatinine level of ≥1.5 times the baseline level (a requisite for the least severe grade of nephrotoxicity under the RIFLE criteria).

  • c Includes incidences of nephrotoxicity classified under the RIFLE criteria and those that do not meet its requirements.

  • d Others included hyperpigmentation (n = 2), drug-related exanthem (n = 5), drug-related fever (n = 1), bronchospasm (n = 1), phlebitis (n = 1), nausea and vomiting (n = 3), diarrhea (n = 3), abdominal pain (n = 1), thrombocytopenia (n = 1), leukopenia (n = 1), and pancytopenia (n = 1).